A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Type 2 Diabetes
Interventions
DRUG

Dapagliflozin

Tablets, Oral, once daily, up to 12 weeks

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, up to 12 weeks

Trial Locations (23)

13210

Suny Upstate Medical University, Syracuse

21204

Model Clinical Research Llc, Baltimore

28801

Mountain Diabetes And Endocrine Center, Asheville

30076

Endocrine Research Solutions, Inc., Roswell

32205

Jacksonville Center For Clinical Research, Jacksonville

44060

Your Diabetes Endocrine Nutrition Group, Mentor

46202

Indiana University, Indianapolis

48109

University Of Michigan, Ann Arbor

53209

Advanced Healthcare S.C., Milwaukee

63128

St. Louis Center For Clinical Research, St Louis

72401

Nea Clinic, Jonesboro

75231

Research Institute Of Dallas, P.A., Dallas

78229

Diabetes And Glandular Disease Research Associates, P.A., San Antonio

93720

Valley Research, Fresno

94904

Bernstein, Richard, Greenbrae

98055

Rainier Clinical Research Center, Renton

R3E 3P4

Local Institution, Winnipeg

E2A 4X7

Local Institution, Bathurst

J8V 2P5

Local Institution, Gatineau

H7T 2P5

Local Institution, Laval

J4N 1L6

Local Institution, Longueuil

H9R 4S3

Local Institution, Pointe-Claire

J1G 5K2

Local Institution, Sherbrooke

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

AstraZeneca

INDUSTRY